Stocks and Investing Stocks and Investing
Thu, September 22, 2022
Wed, September 21, 2022

Brian Cheng Initiated (ADCT) at Buy and Held Target at $5 on, Sep 21st, 2022


Published on 2024-10-27 23:04:01 - WOPRAI, Brian Cheng
  Print publication without navigation


Brian Cheng of JP Morgan, Initiated "ADC Therapeutics SA" (ADCT) at Buy and Held Target at $5 on, Sep 21st, 2022.

Brian has made no other calls on ADCT in the last 4 months.



There are 3 other peers that have a rating on ADCT. Out of the 3 peers that are also analyzing ADCT, 1 agrees with Brian's Rating of Hold. Following is the relevant analyst calls for the last 4 months


  • Matthew Harrison of "Morgan Stanley" Downgraded from Buy to Hold and Decreased Target to $11 on, Friday, September 9th, 2022


These are the ratings of the 2 analyists that currently disagree with Brian


  • Robert Burns of "HC Wainwright & Co." Maintained at Strong Buy with Increased Target to $21 on, Monday, September 19th, 2022
  • Gregory Renza of "RBC Capital" Maintained at Buy with Decreased Target to $29 on, Wednesday, August 10th, 2022

Contributing Sources